NASDAQ:XOMA XOMA (XOMA) Stock Price, News & Analysis $20.33 -0.64 (-3.05%) Closing price 04:00 PM EasternExtended Trading$20.29 -0.04 (-0.20%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About XOMA Stock (NASDAQ:XOMA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get XOMA alerts:Sign Up Key Stats Today's Range$20.00▼$20.9850-Day Range$20.27▼$27.2652-Week Range$19.92▼$35.00Volume11,774 shsAverage Volume40,879 shsMarket Capitalization$243.53 millionP/E RatioN/ADividend YieldN/APrice Target$72.00Consensus RatingBuy Company OverviewXOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.Read More… Remove Ads XOMA Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks90th Percentile Overall ScoreXOMA MarketRank™: XOMA scored higher than 90% of companies evaluated by MarketBeat, and ranked 117th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingXOMA has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageXOMA has only been the subject of 1 research reports in the past 90 days.Read more about XOMA's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for XOMA are expected to grow in the coming year, from ($1.41) to ($0.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of XOMA is -6.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of XOMA is -6.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXOMA has a P/B Ratio of 2.72. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about XOMA's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.47% of the float of XOMA has been sold short.Short Interest Ratio / Days to CoverXOMA has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in XOMA has recently decreased by 7.83%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldXOMA does not currently pay a dividend.Dividend GrowthXOMA does not have a long track record of dividend growth. Sustainability and ESG3.0 / 5Environmental Score-0.22 Percentage of Shares Shorted1.47% of the float of XOMA has been sold short.Short Interest Ratio / Days to CoverXOMA has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in XOMA has recently decreased by 7.83%, indicating that investor sentiment is improving significantly. News and Social Media2.7 / 5News Sentiment0.94 News SentimentXOMA has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for XOMA this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for XOMA on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added XOMA to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, XOMA insiders have sold 11,309.91% more of their company's stock than they have bought. Specifically, they have bought $114,544.00 in company stock and sold $13,069,366.00 in company stock.Percentage Held by InsidersOnly 7.20% of the stock of XOMA is held by insiders.Percentage Held by Institutions95.92% of the stock of XOMA is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about XOMA's insider trading history. Receive XOMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter. Email Address XOMA Stock News HeadlinesBradley Sitko Acquires 4,134 Shares of XOMA Co. (NASDAQ:XOMA) StockMarch 26 at 5:17 AM | insidertrades.comStockNews.com Upgrades XOMA (NASDAQ:XOMA) to "Hold"March 23, 2025 | americanbankingnews.comNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk’s new technology could help launch an entirely new multitrillion-dollar industry.March 28, 2025 | Brownstone Research (Ad)Q1 Earnings Estimate for XOMA Issued By HC WainwrightMarch 23, 2025 | americanbankingnews.comLeerink Partnrs Has Positive Outlook of XOMA FY2025 EarningsMarch 22, 2025 | americanbankingnews.comXOMA Preferred Shares Series A declares $0.539 dividendMarch 20, 2025 | seekingalpha.comXOMA Corp - 8.375% DP PFD B declares $0.5234 dividendMarch 20, 2025 | seekingalpha.comXOMA Royalty Declares Quarterly Preferred Stock DividendsMarch 20, 2025 | gurufocus.comSee More Headlines XOMA Stock Analysis - Frequently Asked Questions How have XOMA shares performed this year? XOMA's stock was trading at $26.28 at the beginning of the year. Since then, XOMA shares have decreased by 20.2% and is now trading at $20.9650. View the best growth stocks for 2025 here. How were XOMA's earnings last quarter? XOMA Co. (NASDAQ:XOMA) announced its quarterly earnings data on Monday, March, 17th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.29) by $0.17. The biotechnology company had revenue of $8.70 million for the quarter, compared to analyst estimates of $8.75 million. XOMA had a negative trailing twelve-month return on equity of 24.95% and a negative net margin of 151.34%. Who are XOMA's major shareholders? Top institutional investors of XOMA include Geode Capital Management LLC (1.55%), Woodline Partners LP (1.33%), Stonepine Capital Management LLC (1.07%) and TLS Advisors LLC (1.01%). Insiders that own company stock include Owen Hughes, James R Neal, Bradley Sitko, Thomas M Burns and Bvf Partners L P/Il. View institutional ownership trends. How do I buy shares of XOMA? Shares of XOMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of XOMA own? Based on aggregate information from My MarketBeat watchlists, some other companies that XOMA investors own include American Water Works (AWK), Waste Connections (WCN), AUO (AUOTY), The RMR Group (RMR), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings3/17/2025Today3/28/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:XOMA CIK791908 Webwww.xoma.com Phone(510) 204-7200Fax510-649-7571Employees10Year Founded1981Price Target and Rating Average Stock Price Target$72.00 High Stock Price Target$104.00 Low Stock Price Target$40.00 Potential Upside/Downside+243.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-40,830,000.00 Net Margins-151.34% Pretax Margin-138.67% Return on Equity-24.95% Return on Assets-9.64% Debt Debt-to-Equity Ratio1.28 Current Ratio7.52 Quick Ratio7.52 Sales & Book Value Annual Sales$10.22 million Price / Sales24.58 Cash FlowN/A Price / Cash FlowN/A Book Value$7.72 per share Price / Book2.72Miscellaneous Outstanding Shares11,979,000Free Float10,935,000Market Cap$251.20 million OptionableOptionable Beta1.00 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:XOMA) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredTrump’s Treasure Map [Pic inside]We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men...Paradigm Press | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredAI Boom Takes a Shocking Turn…A potentially historic moment for retirement Let's make the most of this market together. Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XOMA Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share XOMA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.